Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Pembrolizumab In Combination With R-CHOP for Patients With Untreated, High-Risk, Non-Germinal Center-Derived DLBCL

NCT03995147 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT03995147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03995147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Pembrolizumab In Combination With R-CHOP for Patients With Untreated, High-Risk, Non-Germinal Center-Derived DLBCL
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 29, 2019
Completion date
February 20, 2027
Enrollment
51 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b cell lymphoma, diffuse large b cell lymphoma, high-grade b-cell lymphoma, lymphoma, lymphoma, b-cell